Comparative Pharmacology
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus SYNALAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDROCORTISONE ACETATE versus SYNALAR.
FLUDROCORTISONE ACETATE vs SYNALAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
Corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
0.1 mg orally once daily, range 0.05-0.2 mg/day
Apply a thin layer to affected area twice daily. Max 60 g/week.
None Documented
None Documented
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Terminal elimination half-life: 1-2 hours (topical use); 3-4 hours (systemic absorption after topical application to large areas or occluded skin). Clinical context: short half-life allows once- or twice-daily dosing.
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Renal: <1% as unchanged drug; biliary/fecal: minimal; primarily hepatic metabolism with metabolites excreted renally.
Category D/X
Category C
Corticosteroid
Corticosteroid